Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies
Abstract Heart failure (HF) does not occur in a vacuum and is commonly defined and exacerbated by its co‐morbid conditions. Neurohormonal imbalance and systemic inflammation are some of the key pathomechanisms of HF but also commonly encountered co‐morbidities such as arterial hypertension, diabetes...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13361 |
| _version_ | 1819155464139571200 |
|---|---|
| author | Ana Jorbenadze Marat Fudim Felix Mahfoud Phillip B. Adamson Tarek Bekfani Rolf Wachter Horst Sievert Piotr P. Ponikowski John G. F. Cleland Stefan D. Anker |
| author_facet | Ana Jorbenadze Marat Fudim Felix Mahfoud Phillip B. Adamson Tarek Bekfani Rolf Wachter Horst Sievert Piotr P. Ponikowski John G. F. Cleland Stefan D. Anker |
| author_sort | Ana Jorbenadze |
| collection | DOAJ |
| description | Abstract Heart failure (HF) does not occur in a vacuum and is commonly defined and exacerbated by its co‐morbid conditions. Neurohormonal imbalance and systemic inflammation are some of the key pathomechanisms of HF but also commonly encountered co‐morbidities such as arterial hypertension, diabetes mellitus, cachexia, obesity and sleep‐disordered breathing. A cornerstone of HF management is neurohormonal blockade, which in HF with reduced ejection fraction has been tied to a reduction in morbidity and mortality. Pharmacological treatment effective in patients with HF with reduced ejection fraction did not show substantial effects in HF with preserved ejection fraction. Here, we review novel device‐based therapies using neuromodulation of extra‐cardiac targets to treat cardiometabolic disease. |
| first_indexed | 2024-12-22T15:37:23Z |
| format | Article |
| id | doaj.art-0c371fddcfad48bd89639871af72d173 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-12-22T15:37:23Z |
| publishDate | 2021-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-0c371fddcfad48bd89639871af72d1732022-12-21T18:21:12ZengWileyESC Heart Failure2055-58222021-08-01843327333810.1002/ehf2.13361Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapiesAna Jorbenadze0Marat Fudim1Felix Mahfoud2Phillip B. Adamson3Tarek Bekfani4Rolf Wachter5Horst Sievert6Piotr P. Ponikowski7John G. F. Cleland8Stefan D. Anker9Tbilisi Heart and Vascular Clinic Tbilisi GeorgiaDivision of Cardiology Duke University Medical Center Durham NC USADepartment of Internal Medicine III, Cardiology, Angiology, and Intensive Care Medicine Saarland University Saarbrücken GermanyAbbott Los Angeles CA USADepartment of Internal Medicine I, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Magdeburg Otto von Guericke University Magdeburg GermanyClinic and Polyclinic for Cardiology University Hospital Leipzig Leipzig GermanyCardioVascular Center Frankfurt Frankfurt GermanyCentre for Heart Diseases University Hospital Wroclaw PolandRobertson Centre for Biostatistics University of Glasgow Glasgow UKDivision of Cardiology and Metabolism – Heart Failure, Cachexia & Sarcopenia, Department of Cardiology, Campus Virchow‐Klinikum Charité – Universitätsmedizin Berlin Berlin GermanyAbstract Heart failure (HF) does not occur in a vacuum and is commonly defined and exacerbated by its co‐morbid conditions. Neurohormonal imbalance and systemic inflammation are some of the key pathomechanisms of HF but also commonly encountered co‐morbidities such as arterial hypertension, diabetes mellitus, cachexia, obesity and sleep‐disordered breathing. A cornerstone of HF management is neurohormonal blockade, which in HF with reduced ejection fraction has been tied to a reduction in morbidity and mortality. Pharmacological treatment effective in patients with HF with reduced ejection fraction did not show substantial effects in HF with preserved ejection fraction. Here, we review novel device‐based therapies using neuromodulation of extra‐cardiac targets to treat cardiometabolic disease.https://doi.org/10.1002/ehf2.13361Heart FailureComorbiditiesAutonomic Nervous SystemNeuromodulation |
| spellingShingle | Ana Jorbenadze Marat Fudim Felix Mahfoud Phillip B. Adamson Tarek Bekfani Rolf Wachter Horst Sievert Piotr P. Ponikowski John G. F. Cleland Stefan D. Anker Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies ESC Heart Failure Heart Failure Comorbidities Autonomic Nervous System Neuromodulation |
| title | Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies |
| title_full | Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies |
| title_fullStr | Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies |
| title_full_unstemmed | Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies |
| title_short | Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies |
| title_sort | extra cardiac targets in the management of cardiometabolic disease device based therapies |
| topic | Heart Failure Comorbidities Autonomic Nervous System Neuromodulation |
| url | https://doi.org/10.1002/ehf2.13361 |
| work_keys_str_mv | AT anajorbenadze extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT maratfudim extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT felixmahfoud extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT phillipbadamson extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT tarekbekfani extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT rolfwachter extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT horstsievert extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT piotrpponikowski extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT johngfcleland extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies AT stefandanker extracardiactargetsinthemanagementofcardiometabolicdiseasedevicebasedtherapies |